APOE Modifies the Association Between Aβ Load and Cognition in Cognitively Normal Older Adults

Overview

Journal Neurology

Specialty Neurology

Date 2011 Dec 23

PMID 22189452

Citations 98

Authors

K Kantarci

V Lowe

S A Przybelski

S D Weigand

M L Senjem

R J Ivnik

G M Preboske

R Roberts

Y E Geda

B F Boeve

D S Knopman

R C Petersen

C R Jack Jr

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the relationship between β-amyloid (Aβ) load as measured by [(11)C]-Pittsburgh compound B (PiB) PET and cognitive function in cognitively normal older adults.

Methods: We studied 408 cognitively normal older adults who participated in the population-based Mayo Clinic Study of Aging (MCSA) from January 2009 through March 2011. The participants underwent PiB PET and neuropsychometric testing within 6 months. The association between PiB retention and cognitive function was measured by partial correlation and an interaction with APOE status was tested using linear regression after adjusting for age, sex, and education.

Results: Higher PiB retention was associated with cognitive performance (Spearman partial r = -0.18; p < 0.01), specifically the memory, language, attention/executive, and visual-spatial processing domains in the whole group of participants. The association between PiB retention and cognition was modified by the APOE status on linear regression analysis even after controlling for the differences in the distribution of PiB values among APOE ε4 carriers and noncarriers (p = 0.02). Cognitive performance was associated with the Aβ deposition in the frontal, temporal, and parietal lobe association cortices in APOE ε4 carriers on SPM analysis (p < 0.001).

Conclusion: There is a modest association between PiB retention and cognitive function in cognitively normal older adults and this relationship between Aβ load and cognitive function is modified by APOE status. Whereas Aβ load is associated with greater cognitive impairment in APOE ε4 carriers, the cognitive function in APOE ε4 noncarriers is influenced less by the Aβ load, suggesting that APOE isoforms modulate the harmful effects of Aβ on cognitive function.

Citing Articles

Selenium and Episodic Memory: The Moderating Role of Apolipoprotein E ε4.

Kim S, Keum M, Choe Y, Suh G, Lee B, Kim H Nutrients. 2025; 17(3).

PMID: 39940451 PMC: 11819958. DOI: 10.3390/nu17030595.

APOE from astrocytes restores Alzheimer's Aβ-pathology and DAM-like responses in APOE deficient microglia.

Preman P, Moechars D, Fertan E, Wolfs L, Serneels L, Shah D EMBO Mol Med. 2024; 16(12):3113-3141.

PMID: 39528861 PMC: 11628604. DOI: 10.1038/s44321-024-00162-7.

Retrospective analysis of Braak stage- and APOE4 allele-dependent associations between MR spectroscopy and markers of tau and neurodegeneration in cognitively unimpaired elderly.

Chen A, Gajdosik M, Ahmed W, Ahn S, Babb J, Blessing E Neuroimage. 2024; 297():120742.

PMID: 39029606 PMC: 11404707. DOI: 10.1016/j.neuroimage.2024.120742.

Associations of Amyloid Burden, White Matter Hyperintensities, and Hippocampal Volume With Cognitive Trajectories in the 90+ Study.

Wang J, Ackley S, Woodworth D, Sajjadi S, DeCarli C, Fletcher E Neurology. 2024; 103(3):e209665.

PMID: 39008782 PMC: 11249511. DOI: 10.1212/WNL.0000000000209665.

Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer's disease.

Xia Z, Prescott E, Urbanek A, Wareing H, King M, Olerinyova A Nat Commun. 2024; 15(1):4695.

PMID: 38824138 PMC: 11144216. DOI: 10.1038/s41467-024-49028-z.

References

Rabinovici G, Jagust W . Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009; 21(1):117-28. PMC: 2804478. DOI: 10.3233/BEN-2009-0232. View

Aizenstein H, Nebes R, Saxton J, Price J, Mathis C, Tsopelas N . Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008; 65(11):1509-17. PMC: 2636844. DOI: 10.1001/archneur.65.11.1509. View

Villemagne V, Pike K, Darby D, Maruff P, Savage G, Ng S . Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008; 46(6):1688-97. DOI: 10.1016/j.neuropsychologia.2008.02.008. View

Roe C, Mintun M, DAngelo G, Xiong C, Grant E, Morris J . Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol. 2008; 65(11):1467-71. PMC: 2752218. DOI: 10.1001/archneur.65.11.1467. View

Berlau D, Corrada M, Head E, Kawas C . APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology. 2009; 72(9):829-34. PMC: 2667799. DOI: 10.1212/01.wnl.0000343853.00346.a4. View

Morris J, Roe C, Xiong C, Fagan A, Goate A, Holtzman D . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010; 67(1):122-31. PMC: 2830375. DOI: 10.1002/ana.21843. View

Jack Jr C, Lowe V, Senjem M, Weigand S, Kemp B, Shiung M . 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008; 131(Pt 3):665-80. PMC: 2730157. DOI: 10.1093/brain/awm336. View

Ledesma M, Medina M, Avila J . The in vitro formation of recombinant tau polymers: effect of phosphorylation and glycation. Mol Chem Neuropathol. 1996; 27(3):249-58. DOI: 10.1007/BF02815107. View

Bu G . Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009; 10(5):333-44. PMC: 2908393. DOI: 10.1038/nrn2620. View

10.

Mintun M, Larossa G, Sheline Y, Dence C, Lee S, Mach R . [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006; 67(3):446-52. DOI: 10.1212/01.wnl.0000228230.26044.a4. View

11.

Negash S, Greenwood P, Sunderland T, Parasuraman R, Geda Y, Knopman D . The influence of apolipoprotein E genotype on visuospatial attention dissipates after age 80. Neuropsychology. 2009; 23(1):81-9. PMC: 2721720. DOI: 10.1037/a0014014. View

12.

Jack Jr C, Wiste H, Vemuri P, Weigand S, Senjem M, Zeng G . Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010; 133(11):3336-48. PMC: 2965425. DOI: 10.1093/brain/awq277. View

13.

Breitner J, Wyse B, Anthony J, Welsh-Bohmer K, Steffens D, Norton M . APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology. 1999; 53(2):321-31. DOI: 10.1212/wnl.53.2.321. View

14.

Jagust W, Bandy D, Chen K, Foster N, Landau S, Mathis C . The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010; 6(3):221-9. PMC: 2920531. DOI: 10.1016/j.jalz.2010.03.003. View

15.

Thal L, Kantarci K, Reiman E, Klunk W, Weiner M, Zetterberg H . The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006; 20(1):6-15. PMC: 1820855. DOI: 10.1097/01.wad.0000191420.61260.a8. View

16.

Reiman E, Chen K, Alexander G, Caselli R, Bandy D, Osborne D . Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2003; 101(1):284-9. PMC: 314177. DOI: 10.1073/pnas.2635903100. View

17.

Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D . Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55(3):306-19. DOI: 10.1002/ana.20009. View

18.

Braak H, Braak E . Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-59. DOI: 10.1007/BF00308809. View

19.

Lesne S, Kotilinek L, Ashe K . Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience. 2007; 151(3):745-9. PMC: 2677385. DOI: 10.1016/j.neuroscience.2007.10.054. View

20.

Fagan A, Mintun M, Shah A, Aldea P, Roe C, Mach R . Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2010; 1(8-9):371-80. PMC: 2806678. DOI: 10.1002/emmm.200900048. View